RZLT

Rezolute Inc

• TipRanks·10/16 15:26

  Rezolute: Advancing Ersodetug Clinical Program and Strong Cash Position Underpin Jason McCarthy’s Buy Rating and $14 Price Target

• TipRanks·10/15 11:15

  Cantor Analyst Maintains Buy on Rezolute, Reaffirming $10 Price Target on Increasing Confidence in ersodetug’s Phase 3 and Regulatory Trajectory

• TipRanks·10/15 10:20

  Analysts’ Top Healthcare Picks: Verastem (VSTM), Rezolute (RZLT)

• NASDAQ·10/15 05:14

  Rezolute Completes Enrollment In Phase 3 UpLIFT Study Of Ersodetug For Tumor Hyperinsulinism

• TipRanks·10/14 23:40

  Closing Bell Movers: Rocket Lab sinks on Neutron launch delay

• TipRanks·10/14 21:27

  Rezolute Completes Phase 3 Enrollment for ersodetug

• TipRanks·10/14 20:10

  Rezolute completes enrollment in upLIFT study of ersodetug

• Benzinga·10/14 20:07

  Rezolute Completes Enrollment In Open-Label Phase 3 Study Of Ersodetug In Tumor HI; Topline Data Expected In Mid-December 2026

• Benzinga·10/07 12:39

  This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

• Dow Jones·10/06 20:11

  Rezolute Is Maintained at Buy by Lake Street

• Benzinga·10/06 20:01

  Lake Street Maintains Buy on Rezolute, Raises Price Target to $12

• Seeking Alpha·10/06 19:26

  Rezolute upgraded at Cantor on pre-BLA meeting for ersodetug

• Dow Jones·10/06 13:00

  Rezolute Is Maintained at Market Outperform by Citizens

• Benzinga·10/06 12:58

  Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15

• TipRanks·10/06 12:55

  Rezolute price target raised to $12 from $9 at Lake Street